Trials / Terminated
TerminatedNCT06677203
Study of ASN51 in Adults With Early Alzheimer's Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of ASN51 in Adults With Early Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Asceneuron S.A. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of multiple doses of ASN51 in adult participants with early Alzheimer's disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASN51 | Oral capsules |
| DRUG | Placebo | Oral capsules |
Timeline
- Start date
- 2024-10-16
- Primary completion
- 2024-11-08
- Completion
- 2024-11-08
- First posted
- 2024-11-06
- Last updated
- 2025-06-29
- Results posted
- 2025-06-29
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06677203. Inclusion in this directory is not an endorsement.